Innovation Scorecard for 3,500+ Companies - Identify the Disruptive Potential of the Companies in Your Investment Portfolio
23 nov. 2022 04h23 HE
|
Research and Markets
Dublin, Nov. 23, 2022 (GLOBE NEWSWIRE) -- The "Company Innovation Scorecard - Ranking 3,500 Innovative Companies on Activity, Impact and Disruptive Potential of their Intellectual Property (IP)...
Citrine Global Corp. (OTCQB: CTGL) Files Provisional Patent Application for Balancing Side Effects
16 nov. 2022 10h10 HE
|
Citrine Global, Corp.
Company also Announces the Introduction of GreenFeelsTM Product Lines Tel Aviv, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Citrine Global Corp. (OTCQB: CTGL) is pleased to announce that the Company’s...
Global Digital Rights Management (DRM) Markets, 2022-2027: Expansion of OTT Platforms & Rise in Corporate Need to Protect Data Present Lucrative Opportunities
30 août 2022 06h58 HE
|
Research and Markets
Dublin, Aug. 30, 2022 (GLOBE NEWSWIRE) -- The "Digital Rights Management Market by Component (Solutions and Services), Application (Audio Content, Images, Video Content, Confidential Documents,...
OWP Pharmaceuticals Announces Patent Application for the First-Ever Oral Liquid Formulation of Atomoxetine Hydrochloride for the Treatment of Attention Deficit Hyperactivity Disorder
22 avr. 2021 08h00 HE
|
OWP Pharmaceuticals
NAPERVILLE, Ill., April 22, 2021 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and...
OWP Pharmaceuticals Announces Patent Application for the First-Ever Powder for Oral Liquid Formulation of Duloxetine Hydrochloride for the Treatment of Major Depressive and Generalized Anxiety Disorder
08 juil. 2020 08h00 HE
|
OWP Pharmaceuticals
NAPERVILLE, Ill., July 08, 2020 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc., a privately-held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and...
OWP Pharmaceuticals Announces Pre-IND Acknowledgement and Patent Application for the First-Ever Liquid Oral Suspension Formulation of Quetiapine Fumarate for the Treatment of Schizophrenia and Bipolar Disorder
08 janv. 2020 08h00 HE
|
OWP Pharmaceuticals
NAPERVILLE, Ill., Jan. 08, 2020 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc., a privately-held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and...
REPEAT - Bee Vectoring Technologies Files New Patent for Computer-Controlled Honeybee Hive Dispenser System
11 déc. 2019 08h00 HE
|
Bee Vectoring Technologies International Inc.
MISSISSAUGA, Ontario and SACRAMENTO, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Bee Vectoring Technologies International Inc. (the “Company” or “BVT”) (TSXV: BEE) (OTCQB: BEVVF) today announced that...
Bee Vectoring Technologies Files New Patent for Computer-Controlled Honeybee Hive Dispenser System
11 déc. 2019 01h00 HE
|
Bee Vectoring Technologies International Inc.
MISSISSAUGA, Ontario and SACRAMENTO, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Bee Vectoring Technologies International Inc. (the “Company” or “BVT”) (TSXV: BEE) (OTCQB: BEVVF) today announced that...
OWP Pharmaceuticals Announces a Second IND Approval and Patent Application: The First-Ever Liquid Oral Suspension Formulation of Lamotrigine for the Treatment of Epilepsy and Bipolar Disorder
03 déc. 2019 08h00 HE
|
OWP Pharmaceuticals
NAPERVILLE, Ill., Dec. 03, 2019 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc., a privately-held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and...
NexTech Adds to its IP Portfolio Filing A Non-Provisional Patent Application for Augmented Reality in a Retail Environment
26 mars 2019 07h30 HE
|
NexTech AR Solutions
NEW YORK, NY and TORONTO, ON, March 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – NexTech AR Solutions (the “Company” or “NexTech”) (OTCQB: NEXCF) (CSE: NTAR) (FSE:N29) is pleased to announce that...